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Abstract: This study aimed to determine the associations of targeted metabolomics and hormone
profiles data with lean mass index (LMI), which were estimated using bioelectrical impedance,
in survivors of child severe malnutrition (SM) (n = 69) and controls (n = 77) in Malawi 7 years
after being treated. Linear associations between individual metabolite or hormone and LMI were
determined, including their interaction with nutrition status 7 years prior. Path analysis was
performed to determine structural associations. Lastly, predictive models for LMI were developed
using the metabolome and hormone profile by elastic net regularized regression (EN). Metabolites
including several lipids, amino acids, and hormones were individually associated (p < 0.05 after
false discovery rate correction) with LMI. However, plasma FGF21 (Control: β = −0.02, p = 0.59;
Case: β = −0.14, p < 0.001) and tryptophan (Control: β = 0.15, p = 0.26; Case: β = 0.70, p < 0.001)
were associated with LMI among cases but not among controls (both interaction p-values < 0.01).
Moreover, path analysis revealed that tryptophan mediates the association between child SM and
LMI. EN revealed that most predictors of LMI differed between groups, further indicating altered
metabolic mechanisms driving lean mass accretion among SM survivors later in life.
Keywords: severe malnutrition; non-communicable disease; lean mass; body composition; DOHAD;
hormone; bio-impedance
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1. Introduction
Severe malnutrition (SM) in children remains a global health burden that requires urgent
attention [1]. High mortality among children in the short term is well documented [2,3]. However,
studies on the long-term effects of SM remain limited. While mortality among children with SM has
been declining due to improved community and hospital-based management guidelines, concerns
are growing about longer-term health outcomes of SM survivors [2]. We have previously shown that
survivors of SM have deficient growth, including reduced lean mass compared to children with no
history of SM [4]. Recent reports suggest that early postnatal growth failure and SM are associated with
a higher risk of developing non-communicable diseases (NCD) during adulthood [5–7]. This increased
risk is compounded by changing global dietary habits, which are characterized by higher caloric
consumption, leading to a double burden of malnutrition [8]. The mechanisms driving this risk are
important, but knowledge gaps still remain.
Body composition has a strong influence on NCD risk and can be explained by the capacity-load
model [9]. In this conceptual framework, NCD risk is elevated when the metabolic load exceeds
metabolic capacity [9]. Lean mass is a good marker for metabolic capacity and is inversely associated
with NCD risk [10]. Lower lean mass is also associated with reduced insulin sensitivity [11], increasing
the risk for type 2 diabetes, especially in obese individuals [12]. Furthermore, having lower lean mass
elevates the risk of other complications, such as adverse cardiovascular events among people with
type 2 diabetes [13] and coronary heart disease [14,15]. Mortality among patients with cardiovascular
diseases is lowest among those with high lean mass and low fat mass [16,17]. Therefore, strategies to
improve lean mass may reduce the risk of NCD development and NCD complications in later life.
Identifying the mechanisms linking childhood malnutrition to long-term NCD development could
allow us to identify opportunities for specific interventions to reduce such risk. Therefore, this study
aimed to explore factors associated with lean mass deficit in SM survivors by assessing its association
with the metabolome and hormonal profile among Malawian children.
2. Materials and Methods
2.1. Study Design and Setting
We performed a secondary analysis of data obtained from our previous work in Malawi,
the ChroSAM cohort [4] (Chronic Disease Outcomes following Severe Malnutrition), where plasma
samples were obtained 7 years after being treated for severe malnutrition and previously analyzed
for metabolome and hormonal profiling [18]. Plasma samples were also collected and analyzed
from controls, consisting of sibling and community controls with no history of severe malnutrition.
The original cohort consisted of children treated for complicated SM in 2006–2007 at Queen Elizabeth
Central Hospital in Malawi and were followed 7 years later.
2.2. Participants
The original cohort recruited 352 SM survivors, 217 sibling controls, and 184 age and sex-matched
community controls. In this study, we included children with measured metabolome and hormone
profiles from our previous study [18].
2.3. Variables
The primary outcome was lean mass index (LMI) 7 years after treatment from severe malnutrition.
LMI is the lean mass component of body mass index and is expressed as lean mass by height squared
(kg/m2). LMI is the reciprocal of impedance data obtained from bioelectrical impedance analysis (BIA)
(1/Z) [19]. Independent variables included the metabolome profile and hormone profiles. Age, sex,
human immunodeficiency virus (HIV) status, and former nutritional status (case or control from the
original trial) were also accounted as confounding factors. The group of control participants for this
study included both sibling and community controls.
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2.4. Data Sources and Measurement
LMI was measured using BIA. As shown previously, the reciprocal of impedance (1/Z) provides a robust
marker of LMI without needing population-specific calibration [19]. Targeted metabolomics and hormone
profiling were performed using the AbsoluteIDQ® p180 kit (Biocrates, Innsbruck, Austria) and multiplex
immunoassay (Milliplex® Mag kits, Millipore, Darmstadt, Germany) as previously described [18].
2.5. Study Size
All children with metabolomics, hormone profile, and LMI measurements from our previous
study [18] were included in this current secondary analysis. Therefore, sample size was constrained by
the availability of prior samples, and no new sample size calculations were done.
2.6. Data Analysis
2.6.1. Individual Metabolites and Hormones
First, individual metabolites and hormones were associated with LMI adjusting for age, sex,
HIV status, and early childhood nutritional status (case vs. control) using linear models. For metabolites
showing significant associations (p < 0.05 after false discovery rate (FDR) adjustment), a second model
was generated with interaction between early childhood nutritional status and metabolite or hormone.
These models were compared using analysis of variance, and the interaction term was retained based
on significance of the likelihood ratio (p < 0.05). For variables with significant interaction, a stratified
analysis was performed to determine individual associations within each group.
2.6.2. Path Analysis
Path analysis is a sub-type of structural equation modeling (SEM) that aims to investigate structural
relationships between variables but without the use of latent constructs. We initially generated a
hypothetical structural relationship among early-life SM, LMI, and the metabolites or hormones
whose associations with LMI were different based on nutritional status (significant interaction
between nutrition status and lean mass). Several modifications to this structural relationship were
assessed until a valid and acceptable model was achieved. The SEM model was accepted when the
following goodness-of-fit criteria were met: root mean squared error of approximation (RMSEA) <0.09,
comparative fit index (CFI) >0.9, and Tucker–Lewis index (TLI) >0.9 [20]. SEM was performed using
the lavaan package in R.
2.6.3. Predictive Model for Lean Mass Index Using Metabolome and Hormonal Profile
Multivariable predictive models for LMI were generated separately within cases and controls using
elastic net regularized regression analysis (EN) [21]. The shrinkage of coefficients of non-contributing
variables to zero was controlled by the penalization parameter lambda, which was based on the minimum
cross-validated error following ten-fold cross-validation. Several alpha parameter values were assessed,
and a final value of 0.5 was taken to achieve a compromise between predictive ability and extracting a
fewer number of features. Age, sex, and HIV status were included as covariates. Each EN model was
generated using a training set and then validated on held out data using an 80% to 20% split. Models
were assessed based on the strength and statistical significance of their correlation (R2) and percentage of
root mean squared error of prediction (RMSEP). Bootstrapping was performed for 1000 iterations to
obtain an optimism-adjusted R2 and RMSEP. Analyses were performed in R Version 3.6.
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3. Results
3.1. Study Participants
Metabolomics and hormone profiles from 146 children were used for this analysis after four
children (three siblings and one community control) were excluded due to missing LMI measurements
from the original case-control study [18] (Figure 1). Participant characteristics are shown in Table 1.
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Table 1. Characteristics of study participants in this secondary metabolomics analysis.
SM Survivors Controls Mean Difference ◦ p
n 69 77
Mean age in years (SD) * 9.63 (1.63) 9.95 (2.31) −0.32 0.33
n girls (%) 30 (43%) 34 (44%) 1
n HIV status (%)
<0.001
Negative 44 (64%) 46 (60%)
Positive 20 (29%) 4 (5%)
Unknown 5 (7%) 27 (35%)
Mean mid-upper arm circumference in cm (SD) * 17.12 (1.64) 18.15(2.30) −1.03 0.002
Mean height in cm (SD) * 125.51 (8.90) 129.57 (13.73) −4.06 0. 38
Mean length-for-height z-score (SD) * −1.68 (1.21) −1.37 (1.00) −0.31 0.090
Mean weight-for-age z-score (SD) * −1.44 (0.93) −1.2 (0.88) −0.24 0.210
Mean body-mass index in kg/m2 (SD) * 15.25 (1.33) 15.77 (1.60) −0.52 0.037
Mean lean mass index in (1/Z) × 1000 (SD) * 319.97 (75.36) 378.87 (132.61) 58.9 0.0 1
◦ SM survivors—controls, * calculated from the sample population of study.
This sub-population reflects the demographics of the entire ChroSAM cohort [4], where SM
survivors were observed to hav persistent growth deficits compared to controls, specifically lower
mid-upper arm circumference, smaller height, and lower body mass and LMI indices. HIV was also
mor prevalent amo g SM survivors in our sample population.
3.2. LMI Association with Metabolome and Hormone Profile
Adjusting for age, sex, HIV status, and earlier nutritional status (case or control) as potential
confounders, LMI was found to be associated with a total of 13 metabolites (including seven
phosphatidylcholine (PC) species, two acylcarnitine species (C18 and C18:1), citrulline, tyrosine,
tryptophan and creatinine) and two hormones (IGF1 and FGF21) (FDR-adjusted [22] p < 0.05) (Table 2;
Supplementary Table S1). The R2 values of all individual models exceed 55%, indicating that individual
models comprising of each metabolite or hormone with age, sex, HIV status, and prior nutritional
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status as covariates explain the majority of the variability in LMI. IGF1 was found to have the highest
standardized partial coefficient and partial r2, indicating that it has the strongest association with LMI
compared to the other metabolites and hormones assessed accounting for age, sex, and HIV status.
On the other hand, phosphatidylcholines were the most dominant group among those that showed
significant associations with LMI, all of which were significantly negatively associated with lean mass.
Table 2. Metabolites and hormones significantly associated with lean mass index.
Feature PartialCoefficient * p




IGF1 0.125 <0.001 0.271 0.667 -
FGF21 −0.054 0.027 0.069 0.574 0.007
Lipids
AC C18 −0.054 0.021 0.073 0.576 -
AC C18:1 −0.050 0.046 0.058 0.569 -
PC ae C34:1 −0.065 0.004 0.107 0.592 -
PC aa C32:0 −0.060 0.005 0.095 0.586 -
PC aa C34:1 −0.062 0.006 0.096 0.587 -
PC aa C36:1 −0.064 0.006 0.095 0.586 -
PC aa C32:1 −0.058 0.012 0.082 0.580 -
PC ae C34:0 −0.051 0.027 0.068 0.574 -
PC ae C38:5 −0.052 0.027 0.067 0.573 -
Amino acids
Tryptophan 0.079 <0.001 0.150 0.611 0.003
Tyrosine 0.057 0.012 0.082 0.580 -
Citrulline 0.052 0.040 0.061 0.571 -
Biogenic amine
Creatinine 0.064 0.004 0.100 0.589 -
Ratio and sums
Kynurenine:Tryptophan −0.07 <0.001 0.003 0.590 -
Sum of aromatic amino acids 0.048 0.040 0.059 0.569 -
Sum of lysine, threonine
and tryptophan 0.073 0.001 0.122 0.598 0.03
* Standardized regression coefficient adjusted for age, sex, and HIV status; positive values indicate a positive
association while negative values indicate a negative association,  Coefficient of partial determination, indicating
the variation in lean mass index (LMI) that each metabolite or hormone explains independent of the other covariates
(age, sex, HIV status, and early-life severe malnutrition),  Coefficient of multiple determination (R2) of the full
multivariate model including age, sex, HIV status, and early-life severe malnutrition as covariates, ◦ adjusted for
false discovery rate (FDR), § interaction between feature and early childhood malnutrition status were tested and
only further analyzed if the likelihood ratio test suggested an improved model fit (p < 0.05).
Among those with significant association with LMI, we found that the LMI associations with plasma
FGF21 and tryptophan had a significant interaction with nutritional status, where significant associations
existed in cases but not in controls (Table 2, Figure 2). Cases had significantly higher levels of tryptophan
(log mean difference = 0.15, p = 0.01) but significantly lower levels of FGF21 (log mean difference = −0.51,
p = 0.02) than controls. Circulating FGF21 and tryptophan concentrations were significantly negatively
correlated (β = −1.21, R2 = −0.17, p < 0.0001). Due to the significant association between LMI and
tryptophan, we further determined the association between LMI and kynurenine/tryptophan ratio.
The kynurenine/tryptophan ratio was overall negatively associated with LMI.
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The model suggests a direct negative association between early-life SM and LMI, with this
association partially mediated by plasma tryptophan levels. Early-life SM has a negative impact
on plasma tryptophan levels, whereas tryptophan has a significant positive association with
lean mass. Furthermore, the association between early-life SM and FGF21 is fully mediated by
tryptophan. Moreover, the SEM suggests that a direct association between FGF21 and lean mass is not
statistically significant.
3.4. Prediction of Lean Mass Index Using Metabolome and Hormonal Profiles
To reveal potential differences in LMI associations with metabolome and hormones between cases
and controls, we generated separate multivariable models for each group using EN. The EN models
predicted LMI of controls with high accuracy and robustness with R2 > 0.7 and percentage of root
mean squared error of prediction (RMSEP) ≤15% of mean LMI (Figure 4). However, the model built for
cases was not as strongly predictive with much lower R2 and higher RMSEP values. The EN models
retained nine variables for the control group and 14 for the case group and only age, IGF1, and FGF23
were selected as predictors in both groups. Predictors for LMI among controls were dominated by
lipid species, which showed an overall negative relationship with LMI, whereas the main features for
cases were FGF21, amino acids, including tryptophan, and their metabolites.
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included age, sex, HIV status, 155 plasma metabolite concentrations, and 22 hormones. Correlation
between observed lean mass index and predicted lean mass index among control (a) and SM survivors
(b). Training set included 80% of the observations and the remaining 20% was used for external
validation. RMSEP = root mean squared error of prediction, the numbers in parentheses indicate the
percentage of mean lean mass index. Bootstrap validation of the training set was performed using
1000 iterations. (c) Metabolite and hormone features selected by the elastic net model. Features in blue
are positively associated with lean mass while features in red are negatively associated.
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4. Discussion
In this secondary analysis, we demonstrated that circulating hormones and metabolites were
associated overall with LMI among children in Malawi. However, the associations of tryptophan and
FGF21 toward LMI were only statistically significant among children with a history of SM, whereas these
associations were not observed among controls. This indicates a potential influence of early-life
malnutrition on growth signaling, especially lean mass accretion as influenced by protein or amino
acid availability. This study builds on previous ChroSAM study findings reporting that children who
experienced SM in early childhood were still smaller and had less lean mass, even 7 years post treatment [4].
Results from SEM indicate that the association between early-life SM and LMI was mostly
mediated by plasma tryptophan levels. This observation could be explained by SM in early life
impacting the metabolome, especially tryptophan metabolism, which then has a causal effect on lean
mass. A previous study showed that a tryptophan-deficient diet reduced the skeletal mass in mice [23].
In addition, an earlier study in pigs revealed that tryptophan deficiency led to a reduced protein
synthesis rate in muscles, which recovered upon higher tryptophan intake [24]. This observation
concurred with an even earlier study indicating that dietary tryptophan improved the incorporation of
13C phenylalanine into muscle protein in pigs, indicating that tryptophan improved protein synthesis
beyond its incorporation to protein [25]. These studies demonstrate a potential direct causal relationship
between tryptophan and lean mass accretion. However, these studies focused on muscle mass, which is
only one component of lean mass. Other contributors to lean mass are bones, organs, and other
fat-free components.
In observational clinical studies, serum tryptophan concentration was found to be positively
associated with lean mass in cancer patients with skeletal muscle atrophy [23]. Furthermore, tryptophan
and lysine were positively associated with appendicular lean mass but not with other adiposity-related
measures in older black men [26].
The role of early-life SM in regulating tryptophan metabolism remains to be fully elucidated
by mechanistic studies. For instance, it would be interesting to investigate whether lower
tryptophan levels are due to a persistent downregulation of amino acid transporters in the intestines
(i.e., sodium-dependent neutral amino acid transporter B(0)AT1) or whether an increase in tryptophan
metabolism (enhanced activity of intestinal indoleamine 2,3-dioxygenase or hepatic tryptophan
2,3-dioxygenase) in response to low-grade inflammation persists in children with SM later in life.
FGF21, on the other hand, is increased during dietary restriction [27] or protein malabsorption
or deficiency [28,29]. A study in mice previously showed that tryptophan restriction alone partially
recapitulates the metabolic effect of total amino acid restriction, including FGF21 signaling [30]. Our data
concurs with these previous observations on the negative relationship between FGF21 and tryptophan,
which was independent of malnutrition in early life. FGF21 is an endocrine signal of protein restriction [31].
Taking these markers together, protein or amino acid availability seems to be an underlying determinant
of reduced LMI among SM survivors. However, we did not find evidence that the association between
early-life SM and lean mass is mediated by FGF21, nor that the association between FGF21 and LMI is
independent of tryptophan levels. Hence, it is likely that the link we observed between FGF21 and LMI
was due largely to the significant correlation between tryptophan and FGF21.
Our multivariable prediction models showed that model fit was better for controls (validation R2 = 0.75)
than cases (validation R2 = 0.52). This indicates that more unmeasured factors could explain the
reduced lean mass accretion among SM survivors compared to children with no previous exposure to
SM. In future studies, it will be useful to investigate these underlying factors to fully understand the
long-term consequences of poor early-life nutrition.
Amino acids and amino acid metabolites dominated the top predictors for LMI among
cases. Increased circulating levels of essential amino acids (EAA) such as tryptophan, threonine,
and methionine, and reduced levels of spermine and methionine sulfoxide were shown to be associated
with increased LMI. Indeed, a recent study showed that a deprivation of threonine and tryptophan
drives the systemic metabolic response of total amino acid deprivation and dietary protein depletion [32].
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Therefore, these EAA are limiting amino acids, and their availability from the diet or the body’s
absorptive capacity of these EAA (down-regulation of amino acid transport mechanisms) could strongly
influence LMI.
Taken together, our findings indicate protein or amino acid availability as a potentially modifiable
pathway to improve the health outcomes of SM survivors. Therefore, studies to understand the role of
early-life SM on amino acid metabolism, especially tryptophan, are necessary.
In this study, a limitation is that lean mass was estimated based on BIA rather than measured
with more direct quantification methods such as MRI, the isotope method, or dual-energy X-ray
absorptiometry. However, the form of data expression we used here is independent of population
differences in physique, and it has been validated against criterion methods, demonstrating that it is
robust for ranking individuals within any population [19,33]. Moreover, this is a secondary analysis
of data obtained from a case-control study investigating metabolomics and hormonal differences
between SM survivors and controls [18], and therefore, it was not specifically designed with LMI as an
outcome of interest. We also recognize the high prevalence of HIV, a disease known to affect lean mass,
within this study population (15% HIV positive, 22% unknown HIV status), especially among SM
survivors (27% HIV positive compared to 5% HIV positive among controls). However, we did include
HIV as a confounding factor in both univariable and multivariable analyses to reduce this potential
bias. This follow-up cohort was also recruited from a randomized control trial [34], where more than
half of the children had oedematous malnutrition. Although we were not able to find evidence of any
significant association between prior SM phenotype (i.e., oedematous SAM or severe wasting) on the
metabolome and hormone profile [18], its potential long-term effect could not be discounted. Lastly,
as this is a follow-up cohort after 7 years, survivor bias could influence the associations we observed in
this study. Therefore, validation of these results in an independent cohort is warranted. Prospective
population-based cohorts would be especially helpful in understanding mechanisms since our data
focus on those with a specific type of SM who were sick enough to be admitted to an inpatient feeding
center. In contrast, today’s programs aim to be more proactive and identify children in the community
when less severely malnourished: it would be important to know if such approaches also result in less
long-term metabolic impairment. This would add weight to calls for early treatment and prevention.
Nevertheless, we present some of the first physiological data on the long-term outcomes of
early-life malnutrition on lean mass. Another strength of this work is that the cohort in this study
was recruited from a clinical trial. This means that data collection was standardized and the clinical
histories of the children are available, which ensures that cases are well defined contrary to studies
relying on memory recall or retrospective data.
5. Conclusions
Early-life SM is associated with persistent effects on metabolic processes later in life, which may
influence lean mass in survivors of childhood SAM. The association between early-life SM and lean
mass could be mediated by plasma tryptophan concentrations, implicating the role of tryptophan
metabolism in lean mass accretion among survivors of SM. These findings provide more potential
mechanistic understanding for the increased NCD risk observed in SM survivors later in life.
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